Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04360915
What this trial is testing

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 24
Large-scale testing (Phase 3)UnknownNCT04239833
What this trial is testing

SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 240
Large-scale testing (Phase 3)Active Not RecruitingNCT07183189
What this trial is testing

SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 582
Early research (Phase 1)Study completedNCT01325558
What this trial is testing

ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced Malignant NeoplasmMalignant Solid Tumour
Altor BioScience 30
Large-scale testing (Phase 3)WithdrawnNCT03529084
What this trial is testing

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Who this might be right for
Carcinoma, Non-small Cell Lung
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT05255406
What this trial is testing

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Who this might be right for
Non-Small-Cell Lung Cancer
Fudan University 62
Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Large-scale testing (Phase 3)Active Not RecruitingNCT04923906
What this trial is testing

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 624
Testing effectiveness (Phase 2)Looking for participantsNCT06010329
What this trial is testing

Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Teligene US 66
Testing effectiveness (Phase 2)Ended earlyNCT04984811
What this trial is testing

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNon-Small Cell Lung Carcinoma+2 more
NeoImmuneTech 33
Not applicableUnknownNCT05513664
What this trial is testing

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 80
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)Active Not RecruitingNCT04007744
What this trial is testing

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more
Mayo Clinic 36
Large-scale testing (Phase 3)Active Not RecruitingNCT06140836
What this trial is testing

Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb 190
Testing effectiveness (Phase 2)UnknownNCT02897479
What this trial is testing

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Who this might be right for
Lung Sarcomatoid Carcinoma
Hutchison Medipharma Limited 76
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Not applicableStudy completedNCT02799862
What this trial is testing

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
iOMEDICO AG 408
Testing effectiveness (Phase 2)Looking for participantsNCT06498986
What this trial is testing

BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 40
Not applicableStudy completedNCT01785888
What this trial is testing

Europe-Japan Diagnostic Study for EGFR Testing

Who this might be right for
EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
AstraZeneca 1,311
Large-scale testing (Phase 3)Active Not RecruitingNCT06984588
What this trial is testing

Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
TJ Biopharma Co., Ltd. 450
Next Page